Skip to main content

Table 2 Percentages of resistant phenotypes among Gram-positive and Gram-negative isolates by year, 2013—2016

From: The Tigecycline Evaluation and Surveillance Trial; assessment of the activity of tigecycline and other selected antibiotics against Gram-positive and Gram-negative pathogens from France collected between 2004 and 2016

  E. coli ESBL-positive K. pneumoniae ESBL-positive H. influenzae BL positive P. aeruginosa MDR A. baumannii MDR MRSA
  n % n % n % n % n % n %
2013 46 14.9 75 36.1 39 25.3 33 13.6 11 12.2 84 28.0
2014 43 15.6 85 40.7 27 18.9 21 9.8 10 13.5 76 27.9
2015 47 16.8 71 36.4 36 25.7 11 5.3 7 9.1 50 18.3
2016 20 19.8 34 43.6 20 35.1 3 4.0 7 24.1 24 23.5
  1. BL, β-lactamase, ESBL, extended-spectrum β-lactamase, MDR, multidrug-resistant, MRSA, methicillin-resistant S. aureus